Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
13.10
+0.09 (0.69%)
Dec 20, 2024, 4:00 PM EST - Market closed
Takeda Pharmaceutical Revenue
Takeda Pharmaceutical had revenue of 1.18T JPY in the quarter ending September 30, 2024, with 12.75% growth. This brings the company's revenue in the last twelve months to 4.55T, up 9.43% year-over-year. In the fiscal year ending March 31, 2024, Takeda Pharmaceutical had annual revenue of 4.26T with 5.87% growth.
Revenue (ttm)
4,546.08B JPY
Revenue Growth
+9.43%
P/S Ratio
n/a
Revenue / Employee
92,248,189 JPY
Employees
49,281
Market Cap
41.62B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | 3,291.19B | 1,193.96B | 56.93% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CVS Health | 367.25B |
| Cencora | 293.96B |
| GE HealthCare Technologies | 19.56B |
| IQVIA Holdings | 15.32B |
| Haleon | 15.07B |
| Alcon | 9.76B |
| Agilent Technologies | 6.51B |
| Edwards Lifesciences | 6.31B |
TAK News
- 9 days ago - Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas - Business Wire
- 14 days ago - Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors - Seeking Alpha
- 18 days ago - Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst - Benzinga
- 18 days ago - Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Business Wire
- 4 weeks ago - Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Business Wire
- 7 weeks ago - Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments - Reuters
- 7 weeks ago - Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook - Business Wire